Cite
Cornely OA, Robertson MN, Haider S, et al. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017;72(12):3501doi: 10.1093/jac/dkx382.
Cornely, O. A., Robertson, M. N., Haider, S., Grigg, A., Geddes, M., Aoun, M., Heinz, W. J., Raad, I., Schanz, U., Meyer, R. G., Hammond, S. P., Mullane, K. M., Ostermann, H., Ullmann, A. J., Zimmerli, S., Van Iersel, M. L. P. S., Hepler, D. A., Waskin, H., Kartsonis, N. A., & Maertens, J. (2017). Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. The Journal of antimicrobial chemotherapy, 72(12), 3501. https://doi.org/10.1093/jac/dkx382
Cornely, Oliver A, et al. "Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease." The Journal of antimicrobial chemotherapy vol. 72,12 (2017): 3501. doi: https://doi.org/10.1093/jac/dkx382
Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel MLPS, Hepler DA, Waskin H, Kartsonis NA, Maertens J. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017 Dec 01;72(12):3501. doi: 10.1093/jac/dkx382. PMID: 29029280.
Copy
Download .nbib
